Infertility

The Broken Brown Egg and Progyny Launch 2023 Awareness, Hope, and Activism Grant™ to Help BIPOC Individuals and Couples Expand Their Families

Retrieved on: 
Wednesday, November 1, 2023

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, and The Broken Brown Egg , a nonprofit supporting BIPOC individuals and couples experiencing infertility, today launched the 2023 Awareness, Hope, and Activism (AHA) Grant™.

Key Points: 
  • NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, and The Broken Brown Egg , a nonprofit supporting BIPOC individuals and couples experiencing infertility, today launched the 2023 Awareness, Hope, and Activism (AHA) Grant™.
  • Black women are twice as likely to suffer from infertility but are half as likely to access care than white women ( CDC ).
  • Together, Progyny and The Broken Brown Egg’s mission is to give a person or a couple a new sense of hope and an “AHA” moment to move forward.
  • For full grant application instructions and rules visit the Broken Brown Egg’s grant website, https://thebrokenbrownegg.org/aha-grant .

Family Matters Fertility Centre Launches Innovative Fertility Tourism Program Welcoming Americans

Retrieved on: 
Friday, October 27, 2023

South Africa’s female-led fertility clinic, Family Matters Fertility Centre is distinguished by its first female-led approach, which is designed to meet the individual requirements and convenience of female patients.

Key Points: 
  • South Africa’s female-led fertility clinic, Family Matters Fertility Centre is distinguished by its first female-led approach, which is designed to meet the individual requirements and convenience of female patients.
  • Family Matters Fertility Centre's journey began in February 2020, just before the global COVID-19 pandemic took hold.
  • Family Matters Fertility Centre has launched ‘Fertility Tourist Program’ to cater to a wider audience.
  • Family Matters Fertility Centre is more than just a medical facility; it's a place where dreams of parenthood are fulfilled and hope transforms into joy, welcoming both American and international patients on their path to parenthood.

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Retrieved on: 
Wednesday, November 1, 2023

These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.

Key Points: 
  • These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.
  • It also paves the way for a new research and development model in the global fight against antimicrobial resistance (AMR).
  • Now, the positive results of this landmark Phase 3 trial confirm that zoliflodacin has the potential to tackle the most difficult-to-treat gonorrhea infections.
  • This builds on the critical Phase 2 clinical trial sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

Reimagining Parenthood: Redefining Infertility to Celebrate Every Surrogacy Journey

Retrieved on: 
Monday, November 6, 2023

This new inclusive definition for infertility will allow more people to fulfill their dreams of parenthood.

Key Points: 
  • This new inclusive definition for infertility will allow more people to fulfill their dreams of parenthood.
  • As Fontes states, "We have always believed everyone who wants to be a parent should be able to.
  • This change is particularly significant, given that some insurance plans rely on ASRM's definition of infertility to approve fertility treatments.
  • As a gay dad myself, I understand how hard it is to get started on a surrogacy journey.

TIME Magazine Names UKG One of the World’s Best Companies

Retrieved on: 
Wednesday, November 1, 2023

UKG , a leading provider of HR, payroll, and workforce management solutions for all people, is one of the World’s Best Companies of 2023, according to TIME magazine.

Key Points: 
  • UKG , a leading provider of HR, payroll, and workforce management solutions for all people, is one of the World’s Best Companies of 2023, according to TIME magazine.
  • The inaugural list honors companies from across industries with great workplace cultures, continued business growth, and positive sustainability practices.
  • UKG is also Great Place To Work™ Certified in all 10 countries where it has a significant employee presence.
  • UKG also offers a 45% dollar-for-dollar match on employee retirement-fund contributions in the U.S. and Canada, as well as retirement-matching programs worldwide.

What are the Physical and Psychological Effects of IVF? OB-GYN Tells All in an Infertility Q&A

Retrieved on: 
Monday, October 30, 2023

What questions should people experiencing infertility ask their doctor?

Key Points: 
  • What questions should people experiencing infertility ask their doctor?
  • One of the biggest questions to ask your physician is what they think is going on and whether there is anything unique to your situation.
  • From there, your physician can immediately delve deeper into a possible cause, instead of leaving you contemplating the meaning of your unexplained infertility diagnosis.
  • Unfortunately, there are circumstances where people must stop the IVF process because it takes too much of a mental toll.

Military Families Campaign Raises Awareness of Infertility in the Military Community, Expands Access to Quality Care to Veterans and Active-Duty Service Members

Retrieved on: 
Wednesday, November 1, 2023

HOUSTON, Nov. 1, 2023 /PRNewswire/ -- In celebration of National Veteran and Military Families Month  The Prelude Network® (Prelude) honors the members of the US Armed Forces by expanding accessibility to premium reproductive services to veterans and active-duty personnel through its Military Families Month campaign.

Key Points: 
  • HOUSTON, Nov. 1, 2023 /PRNewswire/ -- In celebration of National Veteran and Military Families Month The Prelude Network ® (Prelude) honors the members of the US Armed Forces by expanding accessibility to premium reproductive services to veterans and active-duty personnel through its Military Families Month campaign.
  • Historically, accessing fertility services has been limited for service members as they must meet stringent criteria set by the Department of Veterans Affairs (VA).
  • "Through our Military Families campaign, Inception is doing its part honor, serve, and support our military members by helping improve that accessibility."
  • For active and retired service members interested in learning more about Prelude's Military Families Month offer, please visit Prelude's Military Families Campaign page.

YourBio Health Announces Expanded Regulatory Approval of its Virtually Painless Blood Collection Device

Retrieved on: 
Tuesday, October 31, 2023

MEDFORD, Mass., Oct. 31, 2023 /PRNewswire/ -- YourBio Health, a Boston-based pioneer in remote, capillary whole blood collection technology, today announced that it has received further regulatory approval for its TAP® Micro Select blood collection device with certification for CE Marking.

Key Points: 
  • MEDFORD, Mass., Oct. 31, 2023 /PRNewswire/ -- YourBio Health, a Boston-based pioneer in remote, capillary whole blood collection technology, today announced that it has received further regulatory approval for its TAP® Micro Select blood collection device with certification for CE Marking.
  • Harry Wilcox, Chief Executive Officer of YourBio Health, said, "With our patented Halo™ technology within the TAP® micro series of blood collection devices, YourBio Health is unique in offering virtually painless blood sample collection using a bladeless microneedle array.
  • Regulatory approval will enable our device's use with commercial blood collection tubes and allow use in kits that revolutionize blood testing in diagnostics and wellness."
  • The TAP® Micro Select blood collection device produces high-quality blood samples in high volumes, which can be processed at any central lab.

Femasys Inc. EU MDR Final Audit Successfully Completed

Retrieved on: 
Thursday, October 26, 2023

ATLANTA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative diagnostic products, today announced that it has successfully completed the Stage 2 European Union (EU) Medical Device Regulation (MDR 2017/745) onsite audit resulting in zero nonconformances and no findings.

Key Points: 
  • – Completion of the European Union Medical Device Regulation (MDR) final audit is the last step in obtaining an MDR certificate and CE marking, confirming Femasys’ compliance with the highest required regulatory standards –
    ATLANTA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative diagnostic products, today announced that it has successfully completed the Stage 2 European Union (EU) Medical Device Regulation (MDR 2017/745) onsite audit resulting in zero nonconformances and no findings.
  • This is the final audit phase in the MDR designation process that was conducted by TUV SUD America Inc., a recognized Auditing Organization and Notified Body.
  • Successful completion of both Stage 1 and Stage 2 MDR audits confirms Femasys is compliant in all areas of MDR and may progress to issuance of the MDR certification, allowing for Femasys’ products to secure CE Marking.
  • “Femasys has worked diligently to implement the requirements of the EU MDR and completion of the final audit with zero nonconformances and no findings demonstrates Femasys has successfully met the new regulations and can soon supply our products to the European Union market,” said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys.

Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons

Retrieved on: 
Wednesday, October 25, 2023

The annual AAGL meeting gathers laparoscopic surgeons worldwide dedicated to the research and advancement of minimally invasive gynecologic procedures.

Key Points: 
  • The annual AAGL meeting gathers laparoscopic surgeons worldwide dedicated to the research and advancement of minimally invasive gynecologic procedures.
  • Femasys is creating accessible innovative options for women, as exemplified by its lead product candidate, FemBloc in late-stage clinical development for permanent birth control and its United States Food and Drug Administration (FDA)-cleared product, FemaSeed® for infertility treatment that is also approved in Canada.
  • The Company is also commercializing complementary diagnostic products, FemVue, FemCath and FemCerv, all of which were internally developed through its in-house manufacturing capabilities, with regulatory approvals in the U.S., Canada and other ex-U.S. territories.
  • Femasys will be exhibiting at booth #1036.